MPS Limited share price
NSE: MPSLTD · ISIN INE943D01017
Key numbers
- Market cap
- ₹ 4,527 Cr
- Current price
- ₹ 2,666.90
- 52-week high / low
- ₹ 2,979 / 1,336
- Stock P/E
- 24.0
- Book value
- ₹ 351.4
- Dividend yield
- 3.11%
- ROCE
- 40.6%
- ROE
- 32.2%
- Debt to equity
- 0.10
- Sales growth (3 yrs)
- 15.4%
- Profit growth (3 yrs)
- 16.6%
- 1-year return
- 16.7%
About MPS Limited
MPS Limited provides platforms and services for content creation, full-service production, and distribution to the publishers, learning companies, corporate institutions, libraries, and content aggregators in India, Europe, the United States, and internationally. It operates through three segments: Research Solutions; Education Solutions; and Corporate Learning. The company offers content authoring and development solutions from PreK12 through higher education and professional development; publishing solutions, including editorial services, proofreading, indexing, project management, journal and book project management, creative studios, rights and permissions, interactive media, composition, and digital production; digital transformation and accessibility solutions; and marketing and customer support solutions. It also provides Digicore, a cloud-based digital publishing platform; MPSTrak, a cloud-based workflow and content management platform for books, journals, reference works, and media; mag+, which publishes content to mobile app; THINK365, an order management fulfillment and BI platform; ScholarStor, a content hosting and delivery platform; SCHOLARLYStats, a cloud-based…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 186 | 194 | 182 | 205 | 224 |
| Operating profit | 50 | 60 | 58 | 68 | 77 |
| Net profit | 35 | 55 | 36 | 47 | 50 |
| EPS (₹) | 20.78 | 32.67 | 20.93 | 27.72 | 29.70 |
Concall summary (2026-07-29)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- We continue to expect the Company to comfortably cross INR 300 crores in EBITDA in FY'27.
- On the guidance itself, Prarthana has reaffirmed our expectation to comfortably cross INR 300 crores in EBITDA, and rather than repeat the number, I want to tell you how much conviction sits behind it.
Growth & demand
- Profit after tax grew 43.0 percent to INR 50.39 crores, and basic EPS came in at INR 29.70, an all-time Q1 high, up from INR 20.78.
- Strip out AJE, which is resetting by design and which Christine will speak to, and the underlying business grew faster still: revenue up 28.4 percent to INR 198.47 crores, EBITDA up 50.5 percent, and the margin expanding close to five points to 32.4 percent.
Margins & costs
- EBITDA was INR 76.96 crores, up 53.0 percent, with the EBITDA margin expanding to 34.3 percent from 27.0 percent a year ago.
- EBITDA grew 37.9 percent, well ahead of revenue, and the segment margin widened to 45.1 percent.
Capex & expansion
- Total cash and cash equivalents stood at INR 138.02 crores as of 30 June, against borrowings of INR 37.63 crores relating to the facility we drew for the Unbound Medicine acquisition.
- A layer that scaled because of the acquisition of AJE.
Balance sheet & cash
- That is operating leverage doing exactly what it is meant to do, with growth converting i nto margin rather than consuming it.
- Second area of attack is, again, let's assume PAT of INR 200 crores, similar cash flow, is normally fairly similar to PAT.
Peers in Publishing
Data for information only, not investment advice. Prices end of day.